TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23127919
Drug: MLV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLV vaccine
Study: 23127919
Drug: Inactivated virus
Normalized name: covid-19, inactivated virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated virus vaccine (one or two doses)
Study: 21558878
Drug: Simvastatin +
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin + Ezetimibe (40 mg/d + 10 mg/d)
Study: 21558878
Drug: Simvastatin +
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin + Placebo (40 mg/d + placebo)
Study: 16579803
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (5000 or 10,000 iu daily)
Study: 12548041
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine stress 99mTc tetrofosmin (DSTF) quantitative gated SPECT
Study: 11508317
Drug: Grape Seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape Seed Extract (GSE) 100 mg bid
Study: 11508317
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cr and GSE (200 microg Cr and 100 mg GSE bid)
Study: 9124549
Drug: Lisinopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (5 mg)
Study: 9124549
Drug: AVP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AVP infusion after lisinopril
Study: 1326902
Drug: gamma-hydroxybutyric acid
Normalized name: gamma-Hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-hydroxybutyric acid (50 mg/kg/day, divided into three daily doses)
Study: 31975413
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 mcg/kg bwt
Study: 31975413
Drug: Romifidine 20
Normalized name: romifidine
DrugBank: Romifidine (DB11543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romifidine 20 mcg/kg bwt
Study: 24831977
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Study: 25907621
Drug: Placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Study: 20464778
Drug: Heliox-powered nebulized
Normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox-powered nebulized albuterol
Study: 20464778
Drug: Air/oxygen-powered nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air/oxygen-powered nebulized albuterol (placebo)
Study: 18824462
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg simvastatin monotherapy
Study: 18824462
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg simvastatin and 10 mg ezetimibe combination therapy
Study: 16000605
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (platinum-based)
Study: 12794583
Drug: Topical nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nifedipine
Study: 12794583
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate
Study: 9927017
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (5.03 g CHO x kg BM(‐1))
Study: 9927017
Drug: Moderate carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate carbohydrate diet (3.89 g CHO x kg BM(‐1))
Study: 7778023
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of M-PLA2, PMN-E, and t-PA
Study: 31734334
Drug: Twice-daily GSP301
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily GSP301 (olopatadine 665 μg and mometasone 25 μg)
Study: 31734334
Drug: Once-daily GSP301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily GSP301 (olopatadine 665 μg and mometasone 50 μg)
Study: 31734334
Drug: Twice-daily olopatadine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily olopatadine (665 μg)
Study: 31734334
Drug: Mometasone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone monotherapy (twice-daily 25 μg or once-daily 50 μg)
Study: 31734334
Drug: Twice-daily mometasone
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily mometasone
Study: 30528849
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (carbohydrates, proteins, electrolytes, osmolarity of 680 mO.L‐1, 300 kcal)
Study: 30528849
Drug: Isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic solution (carbohydrates, electrolytes, osmolarity of 292 mOsm.L‐1, 36 kcal)
Study: 30528849
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between isotonic solution and nutritional supplementation
Study: 24507377
Drug: EMA401 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMA401 (100 mg twice daily)
Study: 19443189
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with purified air
Study: 19443189
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with unfiltered air
Study: 17192489
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg/day) and Fenofibrate (160 mg/day)
Study: 9555866
Drug: Fat-rich breakfast
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-rich breakfast with palmitic acid (21.7 g)
Study: 9555866
Drug: Fat-rich breakfast
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-rich breakfast with stearic acid (18.6 g)
Study: 3419245
Drug: Atropine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (2 mg)
Study: 3933861
Drug: Pirenzepine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (20 mg)
Study: 3419245
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 mg and 2 mg)
Study: 25273077
Drug: S-1 in
Normalized name: PTGS-1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 in combination with leucovorin (SL)
Study: 20228415
Drug: 5-lipoxygenase inhibitor
Normalized name: 5-lipoxygenase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-lipoxygenase inhibitor
Study: 8841865
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with epinephrine (5 micrograms/mL)
Study: 26062189
Drug: Flurphen mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurphen mixture (droperidol injection 1.25 mg and fentanyl citrate injection 0.05 mg diluted to 6 mL with 0.9% sodium chloride solution 4.5 mL) injected at bilateral Shenshu (BL 23) 15 to 20 min before ESWL.
Study: 26062189
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no adjuvant therapy or medication before ESWL.
Study: 22151934
Drug: L‐ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐ascorbic acid 10% + phytic acid 2%
Study: 1955161
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection (1:10,000)
Study: 17561127
Drug: Intraprostatic local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic local anesthesia with 2 ml 1% lidocaine and periprostatic injection of 2 ml saline (Group 1)
Study: 17561127
Drug: Intraprostatic injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic injection of 2 ml saline followed by periprostatic local anesthesia with 2 ml 1% lidocaine (Group 2)
Study: 17561127
Drug: Intraprostatic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic and periprostatic local anesthesia with 2 ml 1% lidocaine (Group 3)
Study: 27506971
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline injection)
Study: 11158797
Drug: Fixed-combination latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-combination latanoprost 0.005%-timolol 0.5% (FC, n = 116)
Study: 1973905
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral dose of gepirone
Study: 1973905
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg gepirone (acute administration)
Study: 1973905
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of gepirone (3-6 weeks)
Study: 13090
Drug: Anisotropine methylbromide
Normalized name: Anisotropine methylbromide
DrugBank: Anisotropine methylbromide (DB00517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisotropine methylbromide (high doses)
Study: 21846343
Drug: Omega-3 polyunsaturated
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 polyunsaturated fatty acids supplement
Study: 21846343
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not given omega-3 supplements)
Study: 17437662
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of different biochemical markers
Study: 15156527
Drug: Dual ACE
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual ACE inhibitor-ARB therapy
Study: 15156527
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and ARBs (combined)
Study: 15156527
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (from trials)
Study: 2689236
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with short-term (ST) 5-FU (575 mg/m2 daily for 4 days before irradiation)
Study: 2689236
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with long-term (LT) 5-FU (750 mg/m2 every 2 weeks for 18 months)
Study: 25805811
Drug: Low-dose Ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Ara-C (LDAC)
Study: 30974973
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (degludec) using FlexTouch1
Study: 16512939
Drug: Algal oil
Normalized name: Algal Oil
DrugBank: Schizochytrium DHA oil (DB11069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algal oil containing 1.5 g DHA and 0.6 g DPA, 4 g oil/d for 4 weeks
Study: 15165387
Drug: Conventional initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional initial treatment (RICE, rest, ice, compression, elevation)
Study: 11167172
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (100 microg kg(‐1) min(‐1))
Study: 9263157
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 30 mg ketoprofen plaster once daily for 5 days (n = 30)
Study: 9263157
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 50 mg ketoprofen (n = 30)
Study: 8390329
Drug: lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 2% with adrenaline 1:200,000 plus 0.1 mEq.ml‐1 sodium bicarbonate
Study: 26561996
Drug: Plasma of
Normalized name: HUMAN IGG POLYCLONAL ANTIBODY DERIVED FROM PLASMA OF TRANSCHROMOSOMAL BOVINE TARGETED TO THE SPIKE PROTEIN OF SARS COV-2
DrugBank: SAB-185 (DB16491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma of argon treatment
Study: 24040851
Drug: Nalfurafine 5
Normalized name: nalfurafine
DrugBank: Nalfurafine (DB13471)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Nalfurafine 5 μg intravenously after each hemodialysis session
Study: 21385240
Drug: Clinical medication
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medication review by community pharmacists
Study: 16136309
Drug: monoHER (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: monoHER (100 mg/m2 to 1,500 mg/m2, administered as an i.v. infusion in 10 min)
Study: 16136309
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml dextrose 5%)
Study: 12933531
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) with micronized progesterone (MP, 100 mg) and conjugated equine estrogen (CEE, 0.625 mg)
Study: 11086281
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg tablets) taken daily for three months, during or outside meals
Study: 11086281
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg tablets)
Study: 9542771
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (25 grams of creatine monohydrate daily for three days)
Study: 8268595
Drug: FUT-175 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT-175 (2 mg/kg/hr)
Study: 8268595
Drug: Control (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sodium heparin 3 mg/kg)
Study: 27020109
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment plans
Study: 27020109
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plans
Study: 24935755
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) with smoking abstinence-contingent incentives (expired CO < 6 ppm; urinary cotinine < 30 ng/ml) for 4 weeks
Study: 26121348
Drug: Esomeprazole 5
Normalized name: esomeprazole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 5 or 10 mg once daily
Study: 12451199
Drug: CPI-1189 100
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-1189 100 mg/day
Study: 12451199
Drug: CPI-1189 50
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-1189 50 mg/day
Study: 10359461
Drug: Individual drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug counseling plus group drug counseling (GDC)
Study: 10359461
Drug: Individual drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug counseling plus GDC
Study: 10359461
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus GDC
Study: 10359461
Drug: Supportive‐expressive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive‐expressive therapy plus GDC
Study: 1664346
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 x 4 mg daily)
Study: 7138720
Drug: i.m. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. morphine
Study: 28468518
Drug: sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual buprenorphine
Study: 7066139
Drug: self-administered i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: self-administered i.v. pethidine
Study: 30407996
Drug: Intravenous Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ketorolac (IVK)
Study: 23159967
Drug: Migraine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine treatment and H. pylori eradication treatment
Study: 23159967
Drug: Migraine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine treatment and placebo (control)
Study: 15902596
Drug: Suppliers medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suppliers medication leaflet
Study: 7720296
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine (100 mcg)
Study: 2119419
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pravastatin once daily
Study: 2119419
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pravastatin and resins
Study: 7435893
Drug: Methylprednisolone 30
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 30 mg/kg in a single dose prior to bypass
Study: 23473342
Drug: meloxicam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam (1 mg/kg PO)
Study: 23473342
Drug: gabapentin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin (15 mg/kg PO)
Study: 23473342
Drug: meloxicam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam (1 mg/kg) and gabapentin (15 mg/kg) PO
Study: 23473342
Drug: flunixin (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunixin (2.2 mg/kg IV)
Study: 22331114
Drug: Ganciclovir 0.15%
Normalized name: GANCICLOVIR 0.15% GEL,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 0.15% ophthalmic gel
Study: 19487950
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g i.v. paracetamol 20 min before and 4, 10 and 16 h after the end of the operation.
Study: 19487950
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g i.v. metamizol scheduled at the same time points as paracetamol.
Study: 19487950
Drug: Placebo scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo scheduled at the same time points as paracetamol.
Study: 19487950
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g i.v. paracetamol
Study: 19487950
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g i.v. metamizol
Study: 17160693
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg BID for 2 weeks escalating to 40 mg BID for 6 weeks
Study: 17160693
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg BID for 8 weeks
Study: 17160693
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg QD for 2 weeks escalating to 40 mg BID for 6 weeks
Study: 11145489
Drug: Eptifibatide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (two 180 microg/kg boluses 10 min apart and a continuous infusion of 2.0 microg/kg/min for 18‐24 h)
Study: 2988393
Drug: Intramuscular supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular supplement of 30 mg of Vitamin D3 in monthly injections of 5 or 10 mg (Group II)
Study: 29462997
Drug: Fibroin protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibroin protein enzymatic hydrolysate (FPEH) at doses of 280 mg, 400 mg, and 600 mg per day for 3 weeks
Study: 29462997
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg FPEH)
Study: 25826729
Drug: 12-week intervention
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week intervention consisting of a very-low-energy diet for the initial 6 weeks followed by a hypocaloric diet, combined with a weekly group multidisciplinary programme (n=27)
Study: 19825849
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg IM methylprednisolone acetate
Study: 16428154
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine 250 mg/day for 16 weeks
Study: 16428154
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral terbinafine 250 mg/day for 16 weeks and topical ciclopirox nail lacquer once daily for 9 months
Study: 8892765
Drug: Exercise rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise rehabilitation program + calcium heparin 12,500 IU subcutaneously 20 to 30 minutes before each exercise session
Study: 1845132
Drug: rhEPO (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (10,000 U five times weekly or 150-450 U/kg)
Study: 1845132
Drug: rhGM-CSF (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF (250 g/m2/day x 14, s.c.) combined with Ara-C (20 mg/m2/day x 14, s.c.)
Study: 30081019
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg body weight, administered intravenously at weeks 0, 4, 8, and 12)
Study: 24385141
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with antioxidant vitamins and minerals
Study: 22196768
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of PF-03654746 plus 60 mg of fexofenadine (group 1)